Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer

Dig Dis Sci. 2006 Dec;51(12):2198-205. doi: 10.1007/s10620-006-9428-2. Epub 2006 Nov 2.

Abstract

We investigated the wide variability of 18F-2-fluoro-2-deoxy-D: -glucose (FDG) uptake, semiquantified as standardized uptake value (SUV), in positron emission tomography (PET) scanning, in 20 patients with colorectal cancer (CRC), including 1 with synchronous hepatic metastasis. The sensitivity of PET in CRC diagnosis was 100%, with a mean SUV of 8.0 (3.1-11.9). Tumor size and depth of invasion were associated with higher SUVs (P=.0004, .042, respectively). Strong glucose transporter-1 (GLUT-1) expression had significantly positive correlation with the SUV (r=.619, P=.003). GLUT-1 expression revealed positive staining in 17 (85%) of the 20 primary lesions. The central part of the tumor, thought to be relatively hypoxic, had stronger GLUT-1 expression and a higher SUV than the periphery, in both the primary tumor and hepatic metastatic foci. Our data suggest that the SUVs of FDG uptake in PET may be a noninvasive biomarker for advanced CRC, indicative of a large hypoxic tumor with deep invasion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / secondary
  • Aged
  • Biomarkers, Tumor / metabolism
  • Colorectal Neoplasms / diagnostic imaging*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / pathology
  • Disease Progression
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Gene Expression Regulation, Neoplastic
  • Glucose Transporter Type 1 / genetics
  • Glucose Transporter Type 1 / metabolism*
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Positron-Emission Tomography*
  • Prognosis
  • Radiopharmaceuticals / pharmacokinetics*
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • Glucose Transporter Type 1
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18